Study Conduct

Report: Vast swathes of human biology untouched by drug discovery programs

Monday, December 5, 2016

Scientists have created a map of all 1,578 licensed drugs and their mechanisms of action—as a means of identifying ‘uncharted waters’ in the search for future treatments. Their analysis of drugs licensed through the FDA reveals that 667 separate proteins in the human body have had drugs developed against them—just an estimated 3.5% of the 20,000 human proteins.

[Read More]

Report: Clinical research benefits the U.K. economy

Friday, December 2, 2016

An independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network and produced by KPMG’s Economics team, provides an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the U.K. The report includes assessment of the economic contribution made to the U.K. economy through clinical research activity supported by the network; analysis to quantify the value of payments made to NHS Trusts for commercial studies, and the value to the NHS of pharmaceuticals used as part of industry-sponsored studies.

[Read More]

AHA, Amazon launch cloud-based precision medicine data marketplace

Tuesday, November 15, 2016

The American Heart Association (AHA) announced a milestone in its strategic collaboration with Amazon Web Services (AWS)—the launch of a global, secure cloud-based data marketplace that will help revolutionize how researchers and clinicians come together as one community to access and analyze rich and diverse data to accelerate solutions for cardiovascular diseases—the No. 1 cause of death worldwide. 

[Read More]

TARGET PharmaSolutions, Bristol-Myers Squibb partner on real world data platform

Tuesday, November 15, 2016

TARGET PharmaSolutions, a clinical data company focused on real world evidence, has announced two new collaborations with Bristol-Myers Squibb to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access to a robust disease state registry that is also linked to a biorepository and patient reported outcomes, providing unique data and insights compared to typical patient registries.

[Read More]

PSR Orphan Experts launches patient organization advisory board

Wednesday, November 9, 2016

PSR Orphan Experts, a specialty orphan drug consulting and clinical research company, has announced the launch of a new Patient Organization Advisory Board to bolster its regulatory and clinical-stage drug development services in rare diseases. The advisory board comprises of up to seven experts from patient organizations, representing a wide range of therapeutic areas, and will play a key role in driving successful orphan drug programs for PSR’s clients.

[Read More]